NASDAQ: GEHC · Medical Devices
GE HealthCare Technologies (GEHC) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values GE HealthCare Technologies (GEHC) at $90.14 a share. The stock last closed at $82.96, which puts the model's fair value 8.7% above the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 16 Nov 2026. GE HealthCare Technologies Inc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $89.09 to $90.14 (+1.2%). The companies the model compares it with now trade on higher multiples: most of the move.
What the model makes of itThe price of $82.96 is 8.7% below it: Fairly valued, on a high evidence grade.
What's nextNext report on 3 Feb 2027. Options prices imply a move of about 9% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give GEHC?
The calibrated range for GEHC over 63 trading days is $75.06 to $92.16. It sits around the last close, and its width comes from the volatility that GEHC's own options imply (30% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $73.68 to $108.17. In 63% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
GE HealthCare Technologies Inc. is a global medical technology company. It creates, manufactures and markets a diverse range of medical devices, services and integrated digital solutions.
Faircurve's model put the fair value of GE HealthCare Technologies Inc. (GEHC) at $90.14 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $89.09, so the fair value moved +1.2%. In the model's own words, "The companies the model compares it with now trade on higher multiples: most of the move." The calibrated range over 63 trading days is $75.06 to $92.16. It is built from the volatility the stock's own options imply and calibrated weekly against realised prices, using 8,038 past valuations refreshed on 14 Nov 2026. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence High. This grade covers input completeness, the number and agreement of comparable companies, and the width of outcomes. It does not say whether the fair value is right.
The model's overall quality score is 49 out of 100, a composite of six factors scored against comparable companies. Stability stands out at 90, with five-year EBITDA margin downside volatility of 0.6 points against a peer median of 2.0 points. Earnings quality scores 0, with free cash flow to net income of 0.87x against a peer median of 1.24x. Growth quality scores 43, with trailing revenue growth of 4.8% against a peer median of 9.1%. The model compares the company with DexCom, Edwards Lifesciences, Boston Scientific, Zimmer Biomet, Penumbra, Stryker and Align Technology, each with its own fair value on the site.
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does GEHC report earnings, and how has the stock reacted?
GE HealthCare Technologies's next earnings report is scheduled for 3 Feb 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 4.2% in either direction through the nearest expiry, about 10 days out. That is the size the market is pricing, not a direction. GEHC's 30 day implied volatility works out to about 8.8% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across GEHC's last 8 reports, ignoring direction, was 6.5%.
What the options market has priced for a month's move in GEHC
How does GEHC score on business quality?
GE HealthCare Technologies's overall quality score is 49 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 65 | 11.9%ROIC | 8.4% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 0 | 0.87xFCF / net income | 1.24x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 43 | 4.8%Revenue growth, trailing | 9.1% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 65 | 0.8%Net buybacks / market value | 1.5% |
| Balance sheetNet debt to EBITDA and interest coverage. | 52 | 1.98xNet debt / EBITDA | 1.98x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 90 | 0.6 ptsEBITDA margin downside volatility, 5y | 2.0 pts |
How does GEHC compare with similar companies?
The companies in medical devices closest to GE HealthCare Technologies in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| DXCM DexCom, Inc. | $81.61 | $73.84 | -9.5% | Fairly valued |
| EW Edwards Lifesciences Corporation | $107.11 | $88.12 | -17.7% | Overvalued |
| BSX Boston Scientific Corporation | $43.69 | $52.05 | +19.1% | Undervalued |
| ZBH Zimmer Biomet Holdings, Inc. | $101.41 | $120.99 | +19.3% | Undervalued |
| GKOS Glaukos Corporation | $244.88 | $228.07 | -6.9% | Data under review |
| PEN Penumbra, Inc. | $320.62 | $296.43 | -7.5% | Fairly valued |
| SYK Stryker Corporation | $310.72 | $275.49 | -11.3% | Fairly valued |
| ALGN Align Technology, Inc. | $165.98 | $200.67 | +20.9% | Undervalued |
What the comparable companies' multiples alone would give for GEHC, the peer-implied price, is $99.21 a share on this run. The fair value weighs that against the company's own multiple.
GE HealthCare Technologies at a glance
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions.
- Market value
- $37.5B
- Sector
- Healthcare
- Industry
- Medical Devices
- Revenue expected, next twelve months
- $22.8B
- Consensus revenue growth, next fiscal year
- +6.0%
- Analysts with estimates
- 13
- Beta to the US market
- 0.51
- First valued by Faircurve
- 1 May 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. GEHC was among them.
How the fair value is worked out: the model prices GE HealthCare Technologies on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for GEHC was $89.09. As of 14 Nov 2026 it is $90.14, a change of +1.2%. The companies the model compares it with now trade on higher multiples: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about GE HealthCare Technologies's valuation
Is GE HealthCare Technologies stock undervalued or overvalued?
On Faircurve's model, GEHC reads as Fairly valued as of 14 Nov 2026. The model's fair value is $90.14 a share against a last close of $82.96, a gap of +8.7%.
What is GEHC's fair value?
$90.14 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $73.68 to $108.17.
What price range does the model give GEHC?
$75.06 to $92.16 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does GE HealthCare Technologies report earnings next?
The next report is scheduled for 3 Feb 2027. Companies can move their dates.
How much has GEHC moved on past earnings reports?
Across its last 8 reports the median two session move was 6.5%, ignoring direction. The largest was -11.2% around the report of 29 Apr 2026.
How confident is the model in this valuation?
The model's evidence grade for GEHC is high. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on GEHC
The model holds no idea open on GEHC today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on GEHC with their outcomes. A free account is enough.